A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).
Condition(s):Lymphoma (Non-Hodgkin’s Lymphoma); Hodgkin’s Disease or Multiple Myeloma; Front Line Mobilization; TransplantationLast Updated:March 24, 2015Completed